Overcoming triple-negative breast cancer (TNBC) resistance to oncolytic virotherapy by histone deacetylase inhibitor, trichostatin A

Abstract

"Triple-negative breast cancer (TNBC) is a tumor classification that lack receptors for the hormones estrogen, progesterone and HER2 protein. These malignancies are characterized to be of poor prognosis, refractoriness to conventional therapy and high rates of recurrence. Virotherapy with oncolytic adenovirus (OAd) consists of cancer selective viruses that replicate, spread, and kill cancer cells by oncolysis, without affecting the normal cells."--Introduction

    Similar works